{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T15:28:59Z","timestamp":1751902139409,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Viatris Pharmaceuticals Japan Inc., Tokyo, Japan."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40801-022-00310-w","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T19:02:26Z","timestamp":1656788546000},"page":"463-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Use of a Network Analysis to Identify Associations and Temporal Patterns Among Non-communicable Diseases in Japan Based on a Large Medical Claims Database"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-7809","authenticated-orcid":false,"given":"Shingo","family":"Higa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Karasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Asami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"310_CR1","unstructured":"World Health Organization. Noncommunicable diseases. 2021. https:\/\/www.who.int\/health-topics\/noncommunicable-diseases#tab=tab_1. Accessed 19 Nov 2021."},{"key":"310_CR2","unstructured":"World Health Organization. Total NCD mortality. 2021. https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/indicator-groups\/indicator-group-details\/GHO\/total-ncd-mortality. Accessed 19 Nov 2021."},{"key":"310_CR3","unstructured":"Bloom DE, Cafiero E, Jan\u00e9-Llopis E, et al. The global economic burden of noncommunicable diseases. 2011. https:\/\/www3.weforum.org\/docs\/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf. Accessed 19 Nov 2021."},{"key":"310_CR4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/1471-2458-11-770","volume":"11","author":"DS Goldberg","year":"2011","unstructured":"Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health. 2011;11:770.","journal-title":"BMC Public Health"},{"issue":"3","key":"310_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/XEB.0000000000000138","volume":"16","author":"K Lisy","year":"2018","unstructured":"Lisy K, Campbell JM, Tufanaru C, et al. The prevalence of disability among people with cancer, cardiovascular disease, chronic respiratory disease and\/or diabetes: a systematic review. Int J Evid Based Healthc. 2018;16(3):154\u201366.","journal-title":"Int J Evid Based Healthc"},{"issue":"11","key":"310_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206702","volume":"13","author":"S Chen","year":"2018","unstructured":"Chen S, Kuhn M, Prettner K, Bloom DE. The macroeconomic burden of noncommunicable diseases in the United States: estimates and projections. PLoS ONE. 2018;13(11): e0206702.","journal-title":"PLoS ONE"},{"key":"310_CR7","unstructured":"World Health Organization. Noncommunicable diseases (NCD) country profiles. 2018. https:\/\/www.who.int\/nmh\/countries\/2018\/jpn_en.pdf?ua=1. Accessed 19 Nov 2021."},{"issue":"10101","key":"310_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S0140-6736(17)31544-1","volume":"390","author":"S Nomura","year":"2017","unstructured":"Nomura S, Sakamoto H, Glenn S, et al. Population health and regional variations of disease burden in Japan, 1990\u20132015: a systematic subnational analysis for the Global Burden of Disease Study 2015. Lancet. 2017;390(10101):1521\u201338.","journal-title":"Lancet"},{"key":"310_CR9","unstructured":"United Nations. World population ageing 2017: highlights. 2017. https:\/\/www.un.org\/en\/development\/desa\/population\/publications\/pdf\/ageing\/WPA2017_Highlights.pdf. Accessed 19 Nov 2021."},{"issue":"4","key":"310_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1751-7176.2011.00434.x","volume":"13","author":"AN Long","year":"2011","unstructured":"Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich). 2011;13(4):244\u201351.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"12","key":"310_CR11","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s11606-007-0313-2","volume":"22","author":"EA Kerr","year":"2007","unstructured":"Kerr EA, Heisler M, Krein SL, et al. Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients\u2019 treatment priorities and self-management? J Gen Intern Med. 2007;22(12):1635\u201340.","journal-title":"J Gen Intern Med"},{"issue":"7062","key":"310_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nature04209","volume":"437","author":"JF Rual","year":"2005","unstructured":"Rual JF, Venkatesan K, Hao T, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature. 2005;437(7062):1173\u20138.","journal-title":"Nature"},{"issue":"21","key":"310_CR13","doi-asserted-by":"publisher","first-page":"8685","DOI":"10.1073\/pnas.0701361104","volume":"104","author":"KI Goh","year":"2007","unstructured":"Goh KI, Cusick ME, Valle D, et al. The human disease network. Proc Natl Acad Sci USA. 2007;104(21):8685\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"310_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000353","volume":"5","author":"CA Hidalgo","year":"2009","unstructured":"Hidalgo CA, Blumm N, Barab\u00e1si AL, Christakis NA. A dynamic network approach for the study of human phenotypes. PLoS Comput Biol. 2009;5(4): e1000353.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"310_CR15","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1038\/s41598-018-22578-1","volume":"8","author":"A Giannoula","year":"2018","unstructured":"Giannoula A, Gutierrez-Sacrist\u00e1n A, Bravo \u00c1, et al. Identifying temporal patterns in patient disease trajectories using dynamic time warping: a population-based study. Sci Rep. 2018;8(1):4216.","journal-title":"Sci Rep"},{"issue":"1","key":"310_CR16","doi-asserted-by":"publisher","first-page":"15561","DOI":"10.1038\/s41598-017-15647-4","volume":"7","author":"E Jeong","year":"2017","unstructured":"Jeong E, Ko K, Oh S, Han HW. Network-based analysis of diagnosis progression patterns using claims data. Sci Rep. 2017;7(1):15561.","journal-title":"Sci Rep"},{"issue":"3","key":"310_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2307\/2530610","volume":"34","author":"D Katz","year":"1978","unstructured":"Katz D, Baptista J, Azen SP, Pike MC. Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics. 1978;34(3):469\u201374.","journal-title":"Biometrics"},{"key":"310_CR18","doi-asserted-by":"publisher","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7(Epub 2018 Nov 8. Erratum in: Lancet. 2019 Jun 22;393(10190):e44. PMID: 30496104; PMCID: PMC6227754).","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"310_CR19","volume-title":"Clinical practice guidelines on the management of low back pain [in Japanese]","author":"Japanese Orthopaedic Association","year":"2019","unstructured":"Japanese Orthopaedic Association. Clinical practice guidelines on the management of low back pain [in Japanese]. 2nd ed. Tokyo: Nankodo; 2019.","edition":"2"},{"key":"310_CR20","unstructured":"Takahashi S, Ohno Y, Someya T, Kamba S, Ozaki N, Mimura M, et al. Diagnostic and statistical manual of mental disorders (DSM-5) [in Japanese]. Tokyo: Igaku-Shoin; 2014."},{"key":"310_CR21","unstructured":"The Japanese Circulation Society, Japanese Heart Failure Society. JCS 2017\/JHFS 2017 guidelines for diagnosis and treatment of acute and chronic heart failure (in Japanese). https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2017\/06\/JCS2017_tsutsui_h.pdf. Accessed 6 Apr 2022."},{"issue":"1","key":"310_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s41109-018-0101-4","volume":"3","author":"B Fotouhi","year":"2018","unstructured":"Fotouhi B, Momeni N, Riolo MA, Buckeridge DL. Statistical methods for constructing disease comorbidity networks from longitudinal inpatient data. Appl Netw Sci. 2018;3(1):46.","journal-title":"Appl Netw Sci."},{"issue":"2","key":"310_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163\u201380.","journal-title":"World Psychiatry"},{"key":"310_CR24","unstructured":"Grant-in-Aid for Scientific Research on Health and Labor Policy Research Project on Intractable Diseases and Research Group on Autoimmune Disease. Sjogren\u2019s syndrome clinical practice guidelines, 2017 [in Japanese]. 2017. https:\/\/minds.jcqhc.or.jp\/docs\/minds\/Sjoegren\u2019s-syndrome\/Sjoegren\u2019s-syndrome.pdf. Accessed 19 Nov 2021."},{"issue":"5","key":"310_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","volume":"43","author":"C Roubille","year":"2014","unstructured":"Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613\u201326.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"310_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10067-014-2750-8","volume":"34","author":"A Nakajima","year":"2015","unstructured":"Nakajima A, Inoue E, Shimizu Y, et al. Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. Clin Rheumatol. 2015;34(3):441\u20139.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"310_CR27","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2169\/naika.106.1433","volume":"106","author":"T Gono","year":"2017","unstructured":"Gono T. Methotrexate (MTX) practice guideline for the treatment of rheumatoid arthritis revised 2016 (simplified version) [in Japanese]. J Jpn Soc Intern Med. 2017;106(7):1433\u20139.","journal-title":"J Jpn Soc Intern Med."},{"issue":"10","key":"310_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/rheumatology\/41.10.1088","volume":"41","author":"SS Yeap","year":"2002","unstructured":"Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford). 2002;41(10):1088\u201394.","journal-title":"Rheumatology (Oxford)"},{"key":"310_CR29","unstructured":"Japan Orthopaedic Association. Clinical practice guideline on the management of osteoarthritis of the hip [in Japanese]. 2nd ed. Tokyo: Nankodo Co Ltd; 2016."},{"issue":"1","key":"310_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00776-013-0496-9","volume":"19","author":"T Yamashita","year":"2014","unstructured":"Yamashita T, Takahashi K, Yonenobu K, Kikuchi S. Prevalence of neuropathic pain in cases with chronic pain related to spinal disorders. J Orthop Sci. 2014;19(1):15\u201321.","journal-title":"J Orthop Sci"},{"key":"310_CR31","unstructured":"The Japan Society of Pain Clinicians. Guidelines for the pharmacotherapy of neuropathic pain [in Japanese]. Revised 2nd edition. Tokyo: Shinko Trading Co Ltd. Publication Department; 2016."},{"key":"310_CR32","unstructured":"Iga J, Uchiyama M, Omori T, et al. Japanese society for the study of depression treatment guidelines II. Major depressive disorder 2016 [in Japanese]. Intern Med. 2020;62(5):542\u20139."},{"issue":"3","key":"310_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4088\/JCP.09m05218gry","volume":"71","author":"JG van Mill","year":"2010","unstructured":"van Mill JG, Hoogendijk WJ, Vogelzangs N, et al. Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. J Clin Psychiatry. 2010;71(3):239\u201346.","journal-title":"J Clin Psychiatry"},{"key":"310_CR34","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.2147\/NDT.S113602","volume":"12","author":"K Watanabe","year":"2016","unstructured":"Watanabe K, Harada E, Inoue T, et al. Perceptions and impact of bipolar disorder in Japan: results of an internet survey. Neuropsychiatr Dis Treat. 2016;12:2981\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9996","key":"310_CR35","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"issue":"4","key":"310_CR36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1176\/ajp.2006.163.4.716","volume":"163","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716\u201323.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"310_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4088\/JCP.10m06176blu","volume":"72","author":"F Lamers","year":"2011","unstructured":"Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2011;72(3):341\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"310_CR38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2169\/naika.108.978","volume":"108","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H. Guidelines for diagnosis and treatment of acute and chronic heart failure (JCS 2017\/JHFS 2017) [in Japanese]. J Jpn Soc Intern Med. 2019;108(5):978\u201385.","journal-title":"J Jpn Soc Intern Med."},{"key":"310_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2261-14-120","volume":"14","author":"D Shima","year":"2014","unstructured":"Shima D, Ii Y, Yamamoto Y, et al. A retrospective, cross-sectional study of real-world values of cardiovascular risk factors using a healthcare database in Japan. BMC Cardiovasc Disord. 2014;14:120.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00310-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-022-00310-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00310-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T04:20:00Z","timestamp":1660969200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-022-00310-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1007\/s40801-022-00310-w","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"15 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was sponsored and funded by Viatris Pharmaceuticals Japan Inc., Tokyo, Japan. The medical writing was supported by Robert Phillips at Clinical Study Support, Inc., Nagoya, Japan and funded by Viatris Pharmaceuticals Japan Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare the following financial interests\/personal relationships. SH, KN, YK, CS, SM, and YA are employees of Viatris Pharmaceuticals Japan Inc., Tokyo, Japan. TL is an employee of Clinical Study Support, Inc., Nagoya, Japan and was involved in the study under contract with Viatris Pharmaceuticals Japan Inc. YY is the President of MinaCare Co., Ltd., Tokyo, Japan that received fees for data usage from Viatris Pharmaceuticals Japan Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with legal and regulatory requirements, including data protection laws. It used data obtained in an anonymized format and containing no personal information. Therefore, informed consent and ethics committee approval were not required because studies using only anonymized data are outside the scope of the Japanese Government\u2019s \u201cEthical Guidelines for Medical and Health Research Involving Human Subjects.\u201d","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The MinaCare data are proprietary to MinaCare, Co., Ltd. and not publicly available for research purposes. Researchers who would like to access the data for research purposes should contact Dr. Yuji Yamamoto (mc_info@minacare.co.jp) to make a data use agreement and pay a data availability fee.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contributions to all of the following: (1) the conception and design of the study, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted and meeting the ICMJE authorship criteria.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}